January 23, 2012
Cellartis is a partner in CardioNet, an EU-project with the aim to develop novel therapeutic tools for identification of heart disease
JANUARY 23, 2012, Gothenburg, Sweden
Enabling functional recovery of the heart after myocardial infarction through cardiac regeneration and repair is a major goal of cardiovascular and regenerative medicine. The CardioNet network, coordinated by the Spanish National Centre for Cardiovascular Research (CNIC), aims at integrating knowledge from holistic molecular and cellular biology approaches in order to better understand the regulation of heart development, homeostasis, and disease. This knowledge will contribute to the identification of new targets and the development of novel therapeutic tools for heart disease. In order to achieve these aims, a diverse interdisciplinary set of partners has been assembled comprising 13 partners throughout Europe.
About Cellectis stem cells: Cellectis stem cells speeds up the development of stem cell technology in particular to find a robust and reproducible way of controlling stem cell production and differentiation. Through the sharing of knowledge and expertise developed by the the two companies forming Cellectis stem cells - Cellartis and Ectycell – Cellectis stem cells becomes a major, long-term and stable industrial player in the global marketplace.
Cellartis AB is a premier provider of stem cell derived products and technologies which will drive unprecedented innovations in drug discovery and regenerative medicine today and in the future. For more information, visit www.cellartis.com.
About Cellectis : Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Cellectis is listed on the NYSE-Euronext Paris Alternext market (code: ALCLS). To find out more, visit www.cellectis.com.